Takeda

News

Gamble by Takeda on unproven cancer mechanism draws a blank

Takeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor – has failed to show a benefit in patients with blood cancers, placing i

News

Takeda spins norovirus vaccine out into separate company

Takeda has decided development of its norovirus vaccine candidate outside Japan will be more efficient if it is spun out into a dedicated company.

Views & Analysis

Doctor hand holding pen and talking to the patient about medication and treatment.

Rare disease: industry, patients and tech join forces on dia...

Takeda’s Adam Zaeske discusses how cross-sector collaboration is shaping a brighter future for rare disease diagnosis.

News

After Sanofi's setbacks, Takeda eyes finish line with its de...

Takeda has revealed long-term clinical trial results with its dengue vaccine that reinforce its safety and efficacy – and help to differentiate it from Sanofi's challenged Dengvaxia shot.

News

Takeda buys Maverick as T-Cell engager research hots up

Takeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer therapies for $525 million, as research into the technology gathers pace.

News

Switch data back Chiesi/Protalix long-acting Fabry drug

Chiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102, as the FDA’s review of the drug continues towards a decision due by

Gamble by Takeda on unproven cancer mechanism draws a blank

Takeda spins norovirus vaccine out into separate company

Rare disease: industry, patients and tech join forces on dia...

After Sanofi's setbacks, Takeda eyes finish line with its de...

Takeda buys Maverick as T-Cell engager research hots up

Switch data back Chiesi/Protalix long-acting Fabry drug

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Takeda

Editor's Picks